Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03709849
Other study ID # Z171100001017104
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2019
Est. completion date August 31, 2020

Study information

Verified date August 2018
Source Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact Kun Ma, Dr.
Phone 86-010-64089750
Email makun12348@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the effectiveness and safety of Bushen Culuan Decoction in the treatment of anovulatory infertility, including anovulatory abnormal uterine bleeding, polycystic ovarian syndrome, hyperprolactinemia, luteinized unruptured follicle syndrome, corpus luteum insufficiency and ovarian insufficiency, through a randomised, double-blinded, double-dummy, parallel positive controlled, adaptive multicenter clinical trial.


Description:

Anovulation is one of the main causes of female infertility. Anovulatory infertility account for a proportion of 25-30% in whole female infertility.

In western medicine, hormone induced ovulation and assisted reproduction technology are two main ways to solve the problem and Clomiphene citrate is the first-line medication in ovulation induction. There are many side effects being reported in the treatment with modern medicine technique such as ovarian hyperstimulation syndrome, complication with uteroscope and puncture egg retrieval, low pregnancy rate with high ovulation rate, potential cancer occuring risk and offspring healthy risk.

Bushen Culuan Decoction is a traditional Chinese medicine recipe with 10 Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong. Previous laboratory and exploratory clinical researches have proved Bushen Culuan Decoction had an exactly efficacy in treating anovulatory infertility safely.

In the first stage, the primary sample size In the study is 528. Half patients will receive Bushen Culuan Decoction and clomiphene citrate placebo, while the other half will receive clomiphene citrate tablets and Bushen Culuan Decoction placebo. When 1/3 of 528 patients complete the treatment, we will analysis the treatment efficacy of 6 diseases separately, and find which of them could be the target diseases of Bushen Culuan Decoction. Then we will modify the sample size depending on the result in first stage, and the research will only be processed in the target diseases being chosen. In the next stage, half patients will receive Bushen Culuan Decoction and clomiphene citrate placebo, while the other half will receive clomiphene citrate tablets and Bushen Culuan Decoction placebo.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 528
Est. completion date August 31, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers No
Gender Female
Age group 21 Years to 40 Years
Eligibility Inclusion Criteria:

1. Aged 21~40 years old;

2. Diagnosed with infertility;

3. Diagnosed with one of below diseases: anovulatory abnormal uterine bleeding, polycystic ovarian syndrome, hyperprolactinemia, luteinized unruptured follicle syndrome, corpus luteum insufficiency and ovarian insufficiency,

4. Diagnosed with TCM syndrome of kidney deficiency and blood stasis syndrome;

5. Patients who has normal sexual intercourse during treatment;

6. Voluntary to sign the informed consent.

Exclusion Criteria:

1. Infertility due to congenital physiological defect or malformation;

2. Infertility due to hereditary factors;

3. Infertility due to oviduct defect, immune factors, uterine fibroid, adenomyosis, endometriosis or hypoplasia of uterus;

4. Spouse has reproductive defects;

5. Severe abnormity of cardiovascular system, liver function, kidney function or hemopoietic system;

6. Allergy to experimental drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
the same as group description including dosage, frequency and duration
control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
the same as group description including dosage, frequency and duration

Locations

Country Name City State
n/a

Sponsors (6)

Lead Sponsor Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijing Fengtai Hospital of Integrated Traditional and Western Medicine, Beijing First Hospital of integrated Chinese and Western Medicine, Beijing Hospital of Traditional Chinese Medicine, Beijing Obstetrics and Gynecology Hospital, Dongzhimen Hospital, Beijing

Outcome

Type Measure Description Time frame Safety issue
Primary Pregnancy Rate Within 12 menstrual cycles from the first time that patient taking medicines. (Each cycle is 28 days)
Secondary Ovulation Rate If the patient participate 1 treatment cycle, the ovulation will be measured 3 menstrual cycles, and if the patient participate 2 treatment cycle, the ovulation will be measured 6 menstrual cycles. At every ovulation phase (about day14 in a period cycle) within 3 or 6 menstrual cycles from the first time that patient taking medicines. (Each cycle is 28 days)
Secondary Basal Body Temperature At every morning within 3 or 6 menstrual cycles from the first time that patient taking medicines to the end of the treatment. (Each cycle is 28 days)
Secondary Endocrine Hormone Including Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Prolactin (PRL), Estradiol (E2), Progesterone(P), Testosterone (T). At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Inhibin B At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Anti-Mullerian Hormone (AMH) At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Antral Follicle Count At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Volume of Uterus and Bilateral Ovaries at the Early Follicle Phase At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Thickness of Endometrium at the Early Follicle Phase At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Type of Endometrium at the Early Follicle Phase The type of endometrium is measured by ultrasound. The type of endometrium contains type A, B, and C. Type A means the endometrium thickness is about 4-9mm, and there is a "trilaminar patterns" in the image. Type B means the endometrium thickness is about 9-12mm, the image shows moderate homogeneous echo. Type C means the endometrium thickness is about 10-14mm with a strong homogeneous echo. The type only represents different forms of endometrium, but not represents endometrium level or grade. At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary the Size of Dominant Follicle At every ovulation phase (about day14 in a period cycle) within 3 or 6 menstrual cycles from the first time that patient taking medicines. (Each cycle is 28 days)
Secondary Peak-Systolic Flow Velocity of Uterus and Bilateral Ovaries At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Pulsatility Index of Uterus and Bilateral Ovaries Pulsatility Index (PI) of Uterus and Bilateral Ovaries is the pulsatility index of uterine arteries and bilateral ovarial arteries. The normal range of uterine PI has no unified standard, but the smaller the index is, the better the endometrial receptivity is. Generally, when uterine PI<2, the endometrial receptivity will be good enough to get zygote implantation, and when uterine PI>3, the endometrial receptivity is too improper to get zygote implantation. At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Resistant Index of Uterus and Bilateral Ovaries Resistant Index (RI) of Uterus and Bilateral Ovaries is the resistant index of uterine arteries and bilateral ovarial arteries. The normal range of uterine RI has no unified standard, but the smaller the index is, the better the endometrial receptivity is. At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Coagulation Indicator Including prothrombin time, activated partial thromboplastin time, fibrinogen and thrombin time At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
Secondary Traditional Chinese Medicine Symptom Score Traditional Chinese Medicine Symptom Score (point) including:
amenorrhea (0-3); delayed menstruation (0-3); scant menstruation (0-3); weakness in lower back, waist and knees (0-3); dizziness and tinnitus (0-3); sexual apathy (0-3); fatigue (0-3); colorless transparent urination(0-3); frequent urination at night (0-3); feeling obstruction with menstruation (0-3); profuse menstruation with dark color (0-3); clot in menstruation (0-3); stabbing pain in lower abdomen area, may aggravating with sexual intercourse (0-3); dysmenorrhea (0-3) The total score will be measured by summing the subitems' score above, and the total score range is 0-42. The higher the score is, the worse the situation is.
At the early follicle phase (day 3 in a period cycle) before the 1st cycle of the treatment and at the 7th cycle of the treatment. (Each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT02244567 - Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women Phase 1
Completed NCT01672801 - Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT N/A
Completed NCT01653743 - Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Phase 3
Completed NCT00579540 - Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels N/A
Terminated NCT05084274 - Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program N/A
Completed NCT03717935 - Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS N/A
Withdrawn NCT01716429 - Healthy Eating for Reproductive Health: Greenville N/A
Active, not recruiting NCT02896452 - Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Recruiting NCT05146063 - LNK in Polycystic Ovary Syndrome With Insulin Resistance
Recruiting NCT06303219 - Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome N/A
Completed NCT02869750 - The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome
Completed NCT01237106 - In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS) N/A
Completed NCT01185704 - Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) Phase 3
Recruiting NCT04029805 - Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels Phase 1/Phase 2
Completed NCT01675843 - Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome Phase 4
Completed NCT01577017 - The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Phase 3
Completed NCT00478504 - Letrozole Versus Clomifene Citrate for Ovulation Induction Phase 4
Completed NCT05215223 - Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome N/A
Completed NCT03358199 - LOD Before IVF/ICSI in PCOS Patients With High AMH N/A
Completed NCT02436226 - Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Phase 4